The V118I mutation as a marker of advanced HIV infection and disease progression

Antiviral Therapy

Volumn 12, Issue 2, 2007, Pages 163-168

  Zaccarelli, Mauro ^a   Tozzi, Valerio ^a   Lorenzini, Patrizia ^a   Forbici, Federica ^a   Narciso, Pasquale ^a   Ceceherini Silberstein, Francesca ^b   Trotta, Maria Paola ^a   Bertoli, Ada ^a   Liuzzi, Giuseppina ^a   Marconi, Patrizia ^a   Mosti, Silvia ^a   Perno, Carlo Federico ^a   Antinori, Andrea ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; ISOLEUCINE; LOGISTIC MODELS; MALE; MUTATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE INHIBITORS; RISK ASSESSMENT; RNA, VIRAL; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT FAILURE; VALINE;

EID: 34147170524     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 4 May 2006. US Department of Health and Human Services, Washingon, DC, USA.
2. Cozzi-Lepri A, Phillips A, Mocroft A, Kirk O, Ruiz L, Lundgren JD. Clinical progression according to HIV drug resistance accumulated on antiretroviral therapy in EuroSIDA. 10th European AIDS Conference/EACS. 17-20 November 2005, Dublin, Ireland. Abstract PS 3/4.
3. Tozzi V, Zaccarelli M, Bonfigli S, et al. Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome. Antivir Ther 2006; 11:553-560.
4. Zaccarelli M, Tozzi V, Lorenzini P, et al.; Collaborative Group for Clinical Use of HIV Genotype Resistance Test (GRT) at National Institute for Infections Diseases Lazzarro Spallanzani. Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS 2005; 19:1081-1089.
5. Cozzi-Lepri A, Ruiz L, Loveday C, et al; EuroSIDA Study Group. Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy. Antivir Ther 2005; 10:791-802.
6. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med 2006; 14:125-130.
7. Larder B, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989; 243:1731-1734.
8. Whitcomb JM, Parkin NT, Chappey C, Hellmann NS, Petropoulos CJ. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis 2003; 188:992-1000.
9. Gianotti N, Galli L, Boeri E, et al. The 118I reverse transcriptase mutation is the only independent genotypic predictor of virologic failure to a stavudine-containing salvage therapy in HIV-1-infected patients. J Acquir Immune Defic Syndr 2006; 41:447-452.
10. Saberg P, Koppel K, Bratt G, et al. The reverse transcriptase (RT) mutation V118I is associated with virologic failure on abacavir-based antiretroviral treatment (ART) in HIV-1 infection. Scand J Infect Dis 2004; 36:40-45.
11. Romano L, Venturi G, Bloor S, et al. Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118. J Infect Dis 2002; 185:898-904.
12. Montes B, Segondy M. Prevalence of the mutational pattern E44D/A and/or V118I in the reverse transcriptase (RT) gene of HIV-1 in relation to treatment with nucleoside analogue RT inhibitors. J Med Virol 2002; 66:299-303.
13. Marcelin AG, Delaugerre C, Wirden M, et al. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. J Med Virol 2004; 72:162-165.